甲基化与多基因风险评分揭示系统性红斑狼疮的不同特征
研究在发现队列(311例患者、400例对照)和复制队列(175例患者、187例对照)中,用17个差异甲基化CpG位点计算SLE甲基化风险评分(MRS),并分析其与HLA-DRB1*03:01、57个非HLA单核苷酸变异的多基因风险评分(PRS)及临床免疫表型的关联。MRS与血清IFN-α2水平、DLE、免疫学受累、多种自身抗体及疾病活动度相关,而PRS与肾炎、抗dsDNA阳性相关,二者无相关性。
要点
- MRS与血清IFN-α2水平、DLE、免疫学受累及抗SSA/SSB/RNP/Sm抗体相关。
- PRS与肾炎、抗dsDNA阳性相关,且与抗SSB抗体患病率降低相关。
- MRS与PRS无相关性,提示遗传与表观遗传通路部分独立。
核心结论
- MRS定义了一个以IFN-α2高、HLA-DRB1*03:01关联、多种自身抗体为特征的SLE亚群,与PRS相关的肾炎风险部分不同。
研究设计与样本
- 发现队列纳入311例符合≥4项ACR-82标准的SLE患者和400例对照,复制队列纳入175例患者和187例对照。
- 全血DNA甲基化用Illumina HM450K芯片检测,MRS基于17个病例对照比较中Δβ≥0.1的独立差异甲基化CpG位点计算。
- 基因分型用Immunochip完成,PRS包含57个非HLA SLE单核苷酸变异。
主要发现
- MRS较高与血清IFN-α2水平强烈相关(P = 1.04 × 10-14)。
- 两个队列中MRS较高均与DLE、免疫学受累及抗SSA/SSB/RNP/Sm自身抗体相关(均P < 0.05),发现队列中与较高疾病活动度相关(P = 1.50 × 10-4)。
- MRS在多种自身抗体患者中升高(P < 1.0 × 10-15),在HLA-DRB1*03:01携带者中也升高(P < 1.0 × 10-3)。
- PRS较高与肾炎、抗dsDNA阳性及抗SSB抗体患病率降低相关(均P < 0.05)。
- MRS与PRS之间未观察到相关性(P = 0.35)。
关键数值与推荐
- MRS由17个独立顶级差异甲基化CpG位点(Δβ≥0.1)计算。
- PRS包含57个非HLA SLE单核苷酸变异。
临床怎么用
- MRS可能有助于识别以IFN-α2高、多种自身抗体为特征的SLE亚群。
- PRS可能提示肾炎和抗dsDNA阳性的风险,与MRS提供互补信息。
- 整合遗传与表观遗传数据可能有助于理解SLE的 divergent 致病通路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aetiopathogenesis of SLE encompasses genetic, environmental and epigenetic factors. We investigated associations between an SLE methylation risk score (MRS), HLA-DRB1*03:01, a non-HLA polygenic risk score (PRS), and clinical and immunological phenotypes. METHODS: DNA methylation in whole blood from patients fulfilling ≥4 ACR-82 criteria and from controls was investigated using the Illumina HM450K array. The discovery cohort included 311 patients and 400 controls, and the replication cohort comprised 175 patients and 187 controls. Seventeen independent, top differentially methylated CpG sites (Δβ of ≥0.1) from case-control comparisons were used to calculate the MRS. Genotyping was performed using the Immunochip, and the PRS included 57 non-HLA SLE single-nucleotide variants. Clinical data were collected from patient charts, and serum IFN-α2 was measured using Simoa. RESULTS: Higher MRS was strongly associated with serum IFN-α2 levels (P = 1.04 × 10-14). In both cohorts, higher MRS was associated with DLE, immunologic involvement, and anti-SSA/SSB/RNP/Sm autoantibodies (all P < 0.05), and with higher disease activity in the discovery cohort (P = 1.50 × 10-4). MRS was also elevated in patients with multiple autoantibodies (P < 1.0 × 10-15) and in HLA-DRB1*03:01 carriers (P < 1.0 × 10-3). In contrast, higher PRS was associated with nephritis, anti-dsDNA positivity, and lower prevalence of anti-SSB antibodies (all P < 0.05). No correlation was observed between the MRS and the PRS (P = 0.35). CONCLUSION: The MRS defines an IFN-high, HLA-DRB1*03:01-linked SLE subset with multiple autoantibodies, partly distinct from PRS-associated nephritis risk, highlighting potentially divergent pathogenic pathways. These findings underscore the value of integrating genetic and epigenetic data to better understand underlying disease mechanisms in SLE.
引用
- Vestin H, Oparina N, Eloranta ML, et al. Methylation and polygenic risk scores capture different features of Systemic Lupus Erythematosus. Rheumatology (Oxford). 2026. PMID: 42434801. doi:10.1093/rheumatology/keag359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。